Is this what happens when research moves from universities to the private sector? Not sharing data and results seems par for the course for things like proprietary algorithms. Why would biotech be any different?
In fairness, one good thing about commercialisation is that if they don’t produce the goods in the end, it fails. In pure research it can go unnoticed much longer.
